We have previously demonstrated that endothelial targeting of
gold nanoparticles followed by external beam irradiation can cause specific
tumor vascular disruption in mouse models of
cancer. The induced vascular damage may lead to changes in
tumor physiology, including tumor hypoxia, thereby compromising future therapeutic interventions. In this study, we investigate the dynamic changes in tumor hypoxia mediated by targeted
gold nanoparticles and clinical
radiation therapy (RT). By using noninvasive whole-body fluorescence imaging, tumor hypoxia was measured at baseline, on day 2 and day 13, post-
tumor vascular disruption. A 2.5-fold increase (P<0.05) in tumor hypoxia was measured two days after combined
therapy, resolving by day 13. In addition, the combination of vascular-targeted
gold nanoparticles and
radiation therapy resulted in a significant (P<0.05) suppression of
tumor growth. This is the first study to demonstrate the
tumor hypoxic physiological response and recovery after delivery of vascular-targeted
gold nanoparticles followed by clinical
radiation therapy in a human
non-small cell lung cancer athymic Foxn1nu mouse model.